cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Ocugen Inc
139 own
88 watching
Current Price
$0.79
$-0.04
(-5.29%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
272.75M
52-Week High
52-Week High
2.10500
52-Week Low
52-Week Low
0.49100000
Average Volume
Average Volume
3.98M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization272.75M
icon52-Week High2.10500
icon52-Week Low0.49100000
iconAverage Volume3.98M
iconDividend Yield--
iconP/E Ratio--
What does the Ocugen Inc do?
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Read More
How much money does Ocugen Inc make?
News & Events about Ocugen Inc.
Globe Newswire
1 year ago
MALVERN, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Zolmax
1 year ago
Ocugen, Inc. (NASDAQ:OCGN Get Rating) Director Junge Zhang purchased 200,278 shares of the companys stock in a transaction on Wednesday, June 14th. The stock was bought at an average price of $0.50 per share, for a total transaction of $100,139.00. Following the completion of the purchase, the ...
Globe Newswire
1 year ago
Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)Received Orphan Drug Designation (ODD) from the FDA for OCU410ST for the ...
Globe Newswire
1 year ago
MALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live ...
Globe Newswire
1 year ago
Favorable safety and tolerability profile related to OCU400 investigational product candidateInitial clinical data from low and medium dose cohorts indicates positive trend in Multi-luminance mobility testing and Best-Corrected Visual Acuity scores for OCU400 treated eyes71.4% (5/7) of OCU400 ...
Frequently Asked Questions
Frequently Asked Questions
What is Ocugen Inc share price today?
plus_minus_icon
Can Indians buy Ocugen Inc shares?
plus_minus_icon
How can I buy Ocugen Inc shares from India?
plus_minus_icon
Can Fractional shares of Ocugen Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Ocugen Inc stocks?
plus_minus_icon
What is today’s traded volume of Ocugen Inc?
plus_minus_icon
What is today’s market capitalisation of Ocugen Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Ocugen Inc?
plus_minus_icon
What percentage is Ocugen Inc down from its 52-Week High?
plus_minus_icon
What percentage is Ocugen Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.79
$-0.04
(-5.29%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
VERRICA PHARMACEUTICALS INC
VERRICA PHARMACEUTICALS INC
$0.66
$-0.04 (-5.71 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$2.00
$-0.80 (-28.75 %)
GENERATION BIO CO
GENERATION BIO CO
$0.93
$0.02 (1.76 %)
ADC Therapeutics SA
ADC Therapeutics SA
$1.88
$-0.04 (-2.08 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
VERRICA PHARMACEUTICALS INC
VERRICA PHARMACEUTICALS INC
$0.66
$-0.04 (-5.71 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$2.00
$-0.80 (-28.75 %)
GENERATION BIO CO
GENERATION BIO CO
$0.93
$0.02 (1.76 %)
ADC Therapeutics SA
ADC Therapeutics SA
$1.88
$-0.04 (-2.08 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00